Low Level Light Therapy: The Path Forward


OSA Incubator

Low Level Light Therapy: the Path Forward

20-22 August 2014
OSA Headquarters, Washington, DC, USA

Hosted by:

Juanita Anders
Uniformed Services University of the Health Sciences

Praveen Arany
National Institute of Health

James Carroll
THOR Photomedicine Ltd

Michael R Hamblin
Harvard Medical School

Donald E. Patthoff, DDS

Low Level Light Therapy (LLLT) also known as photobiomodulation (PBM), a light therapy using visible and NIR radiation, is almost 50 years old. Hundreds of positive clinical trials and thousands of laboratory studies have been published yet LLLT/PBM has not been adopted by mainstream medicine. This meeting will address the reasons for this failure and identify paths forward.

Background

LLLT/PBM is absorbed by endogenous chromophores catalysing non-thermal, non-cytotoxic, biological reactions. It has been shown in clinical trials and laboratory studies that LLLT / PBM has tissue regenerative effects (skin, tendon, muscle, bone, nerves, spinal cord and cerebral cortex). It has very good anti-inflammatory effects, analgesic effects; it improves function of healthy organs (brain, muscle) and also has cytoprotective effects (brain, muscle).



There are about 400 hundred controlled clinical trials and thousands of laboratory studies investigating the biological mechanisms, irradiation parameters and dose with good results seen in some of the world’s most challenging clinical conditions including: traumatic brain injury, stroke, spinal cord injury, peripheral nerve injuries, macular degeneration, heart disease, osteoarthritis, non-healing diabetic wounds, postherpetic neuralgia, as well as less challenging conditions such as sports injuries and skin conditions.

The clinical trials and laboratory studies consistently show good repeatable results where drugs and surgery are failing, yet LLLT has not been widely adopted by mainstream medicine. Why is this? The reason for this depends on who you ask.

According to:
  • Scientists it’s a: lack of mechanism, parameters and dose evidence
  • Doctors it’s a: lack of large clinical trials / systematic reviews
  • Hospital administrators it’s a: lack of reimbursement
  • Insurance it’s a: lack of cost / benefit evidence
  • Industry representatives it’s a: marketing hype / misinformation
  • Development professionals it’s a: lack of a focused central tech/research/clinical corridor
This Incubator will bring together researchers, clinicians, industry representatives and others to explore the science behind LLLT and discuss the path forward.  Through invited talks and group discussions the questions that will be explored include:
  1. What is real and what is not?
  2. What is holding us back?
  3. What do we need to move forward?

Sponsors
 
 


Meeting Schedule (view full agenda)
The program, including breakfasts and lunches, will be held at OSA Headquarters, 2010 Massachusetts Ave, NW, Washington, DC 20036.

Day 1: 20 August 2014
  • Begins with dinner, location to be determined, at 18:00
Day 2: 21 August 2014
  • Breakfast begins at 8:00
  • Program begins at 8:30, lunch is included onsite
  • Dinner, location to be determined, begins at 18:00
Day 3: 22 August 2014
  • Breakfast begins at 8:00
  • Program begins at 8:30, lunch is included onsite
  • Program adjourns at 15:30

Are you interested in attending?
A limited number of spots have been set aside at this invitation only meeting for interested individuals to apply for. Please send a brief letter of interest along with a CV to the hosts at osaincubator@osa.org.

Additional Information
This page will provide you with information on receiving a letter of invitation if required for your visa as well as additional logistical and area information.